D. Boral Capital Reiterates “Buy” Rating for VolitionRX (NYSEAMERICAN:VNRX)

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $3.00 price target on the medical research company’s stock.

Separately, Maxim Group lowered VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $2.50.

VolitionRX Stock Down 5.0%

Shares of VNRX stock opened at $0.19 on Wednesday. VolitionRX has a 12 month low of $0.17 and a 12 month high of $0.94. The company has a market cap of $25.76 million, a PE ratio of -0.83 and a beta of 1.33. The business’s 50 day moving average is $0.24 and its two-hundred day moving average is $0.37.

Institutional Investors Weigh In On VolitionRX

Institutional investors and hedge funds have recently made changes to their positions in the company. Lagoda Investment Management L.P. increased its position in shares of VolitionRX by 6.7% during the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after purchasing an additional 782,000 shares in the last quarter. Armistice Capital LLC grew its stake in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC boosted its holdings in shares of VolitionRX by 15.6% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock worth $157,000 after acquiring an additional 31,300 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.